Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes

Fig. 5

Summary of NFE2L2 mutations and survival outcomes in patients receiving ICIs. (A) Kaplan–Meier survival curves of OS between NFE2L2 MU and NFE2L2 WT groups in the pooled cohort composed of DFCI, MSK, MSK1661, OAK, Pender, POPLAR and PUCH cohorts. (B) Association of NFE2L2 mutation with OS stratified by study with ICIs treatment. The proportion of CR/PR to ICIs in NFE2L2 mutated patients from the pooled (C, n = 908) and NSCLC (G, n = 491) cohorts. Kaplan–Meier survival curves of OS among Nrf2-activating MU, Nrf2-inactivating MU, unknown NFE2L2 MU and WT groups from pan cancer (D) and NSCLC (H) with ICIs treatment. (E) The multivariate Cox regression analysis for OS in patients with ICIs treatment. (F) Meta-analysis for NSCLC and bladder cancer to summarize association of NFE2L2 mutation with OS after ICIs treatment

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us